Nurse and Patient Perceptions and Preferences for Subcutaneous Autoinjectors for Inflammatory Joint or Bowel Disease: Findings from a European Survey.

ABSTRACT:

Introduction

Imraldi™ is a biosimilar of the anti-tumor necrosis factor (TNF) monoclonal antibody adalimumab and was recently approved in Europe for the treatment of various inflammatory conditions. Imraldi is administered via an autoinjector device that features distinct design attributes compared with other biologic TNF inhibitor autoinjectors, such as the Humira (adalimumab) Pen® and Enbrel® (etanercept) MyClic® Pen were developed by the relevant pharmaceutical companies. The aim of this study was to evaluate patients' and nurses' preferences for the Imraldi versus Humira or Enbrel MyClic autoinjectors in the UK and Germany.

Methods

Patients with inflammatory joint or bowel disease and nurses with experience in educating patients with these conditions on self-injection pa

SUBMITTER: Fenwick S 

PROVIDER: S-EPMC6514039 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature